Last updated: 2026-09-06 02:55:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Pharming Group N.V. ADS, each representing 10 (PHAR) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $11,34, with a market capitalization of $792,71M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $9,62 to $21,34. This page covers its latest market performance, valuation, price trends and company information.
$792,71M | |
$11,16 | |
$5 390,00 | |
$6,10 | |
$11,46 | |
5,15K | |
-- | |
-- | |
$21,34 | |
$9,62 | |
-- | |
-- |
Pharming Group N.V. ADS, each representing 10 (PHAR) last closed at $11,46 as of 2026-09-04 23:31:00, unchanged from the previous close of $11,46.
During the latest regular trading session, PHAR traded between $6,10 and $5 390,00, with a volume of 5,15K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Pharming Group N.V. ADS, each representing 10 (PHAR) moved from $11,50 to $11,34, representing a decline of 1,43% ($0,16).
The stock traded between $11,16 and $11,72 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 11,23 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 14,6%
PHAR is currently trading at $11,34, placing it 14,6% of the way from its 52-week low of $9,62 to its 52-week high of $21,34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
| Employees | 409 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Pharming Group N.V. ADS, each representing 10 (PHAR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.